- Home
- FENC vs KIO Comparison
FENC vs KIO Comparison
Compare FENC & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FENC | KIO |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 455.8M |
| IPO Year | 2010 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FENC | KIO |
|---|---|---|
| Price | $10.88 | $10.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 239.3K | 177.2K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $176.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $10.65 |
| 52 Week High | $13.25 | $12.76 |
Technical Indicators
Market Signals| Indicator | FENC | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 27.62 |
| Support Level | $10.88 | N/A |
| Resistance Level | $11.28 | $11.26 |
| Average True Range (ATR) | 0.50 | 0.08 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 28.44 | 14.41 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.